Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data

Claudio Borghi
Arrigo FG Cicero
“D. Campanacci” Clinical Medicine and Applied Biotechnology Department, Alma Mater Studiorum, University of Bologna, Italy

Abstract: Angiotensin-converting enzyme (ACE) inhibitors effectively interfere with the renin-angiotensin system and exert various beneficial actions on vascular structure and function beyond their blood pressure-lowering effects. Zofenopril, a potent sulphhydryl ACE inhibitor, is characterized by high lipophilicity, sustained cardiac ACE inhibition, and antioxidant and tissue protective activities. Its ancillary properties, such as antioxidant activity and cardiovascular (CV) protection, make this drug potentially suitable for the treatment and prevention of certain CV diseases. The Survival of Myocardial Infarction Long term Evaluation trials have demonstrated that the early administration of zofenopril to patients with acute myocardial infarction is associated with a significant reduction in the 6-week occurrence of major CV events in high-risk patients with anterior non-thrombolysed myocardial infarction. The fixed combination of zofenopril–hydrochlorothiazide (HCTZ) 30/12.5 mg/day is approved for the management of mild-to-moderate hypertension in different European countries. In clinical trials comparing zofenopril–HCTZ with each agent administered as monotherapy, combination therapy was clearly more effective in normalizing blood pressure (BP). In addition, combination therapy provided sustained and consistent BP control over the entire 24 hour dosing interval. The efficacy and safety profile of zofenopril–HCTZ highlights that this combination is a potentially useful addition to currently available therapy for patients with BP inadequately controlled by monotherapy, as well as for patients who require more rapid and intensive BP control.

Keywords: zofenopril, hydrochlorothiazide, mild-to-moderate hypertension, combination therapy

Introduction

Hypertension is the most commonly occurring independent risk factor for cardiovascular (CV) disease in both developed and developing countries (Ezzati et al 2002). The life-long prevalence of developing hypertension after the sixth decade of life is reportedly 90% (Franklin et al 2001). On the other hand, effective treatment of hypertension is associated with a reduction in adverse CV events (Collins and MacMahon 1994; Hansson et al 1998). A meta-analysis of data sampled in more than 47,000 patients showed that a sustained reduction of 5 mmHg to 6 mmHg in diastolic blood pressure (DBP) resulted in a risk reduction of more than 50% for heart failure, up to 40% for stroke and 20% to 25% for coronary heart disease (Vasan et al 2001). Data from the Hypertension Optimal Treatment (HOT) trial, evaluating approximately 19,000 patients reported that the lowest incidence of major cardiovascular events occurred at a mean achieved DBP of 82.6 mmHg. In addition, in a subgroup analysis, a 50% reduction in major CV events was observed in patients with hypertension and diabetes randomized to a target DBP of ≤80 mmHg (Hansson et al 1998; WHO–ISH 2003).
Current guidelines for the management of hypertension recommend treating all hypertensive patients to target systolic blood pressure (SBP)/diastolic blood pressure (DBP) values of ≤140/90 mmHg, and for patients with hypertension and comorbidities such as diabetes or renal disease to a target of <130/80 mmHg (ESH–ESC 2003; JNC-7 2003).

Beyond these recommendations, according to recent US data (Hajjar and Kotchen 2003), a large proportion of the hypertensive population (about 50%) are unaware of their high BP values and, consequently, are not currently treated for hypertension. Among those who are aware and treated for hypertension, the actual degree of adequate BP control is far from satisfactory, and does not attain the 30% level of treated patients across almost all Western countries (Wang and Vasan 2005).

Similar results have been provided by an extensive review of the extent of blood pressure management in European countries (EUROASPIRE II 2001). Poor BP control is responsible for a significant increase in the economic burden of treating hypertension, since it increases the proportion of patients who do not achieve any clinical benefit from treatment, despite their involvement in a costly treatment program. Several different reasons have been identified to explain the poor extent of BP control, including: 1) inadequate compliance to treatment; 2) insufficient use of drug combinations; and 3) the high proportion of patients who withdraw from treatment because of incomplete BP control (Ambrosioni et al 2000).

The main ways to improve the patient compliance to antihypertensive treatment appear to be the use of first-line therapy that are: 1) well tolerated; 2) mono-administered; 3) efficacious (JNC 7 2003).

In this context, angiotensin-converting enzyme (ACE) inhibitors are one of the most safe and efficacious class of antihypertensive drugs (Khalil et al 2001).

**Rationale for combination therapy**

It is now recognized that the majority of patients will require at least two antihypertensive drugs to achieve optimal BP control (Hansson et al 1998; Kearney et al 2005). The European Society of Hypertension – European Society of Cardiology (ESH–ESC) guidelines recommend the use of either low-dose monotherapy or low-dose combination therapy with two agents (eg, a beta-blocker and a diuretic or an ACE inhibitor and a diuretic) (ESH–ESC 2003). The Joint National Committee 7 (JNC-7) report states that the addition of a second agent from a different class should be initiated when the use of monotherapy fails to achieve adequate control of BP (JNC-7 2003).

From a prognostic point of view, what appears to be more relevant in the first choice of an antihypertensive agent is its efficacy in normalizing BP: the HOT trial demonstrated that greater BP reductions and higher response rates are achieved with the use of combination therapy (Hansson et al 1997, 1998). In this trial, a total of 85% of patients achieved a DBP of ≤90 mmHg, but only approximately one-third of patients remained on monotherapy. Interestingly, 27% of patients had well controlled BP when treated according to step 2 treatment, consisting of a low-dose combination of two agents.

A lack of patient compliance is not sufficient to completely account for the poor treatment rates and low target attainment observed in patients with hypertension (Wetzels et al 2004). As demonstrated by the HOT trial, monotherapy simply does not result in BP lowering to or below target levels in the majority of patients.

Fixed-dose combination therapy is likely to be more effective in achieving BP goals and result in greater patient compliance than titrating individual doses of two single agents (Moser 2003). Furthermore, fixed dose combination therapy offers beneficial BP lowering effects while minimizing the adverse effects that are potentially associated with the titration of each agent administered singly (Mancia and Grassi 1999; Zanchetti 1999).

An effective fixed-dose two-drug combination should have: complementary mechanisms of action; an antihypertensive effect that is at least as, if not more, effective than either agent administered singly or as sequential combination therapy; enhanced ability to offer end-organ protection, and minimal adverse effects (including, hemodynamic and metabolic effects) (Mancia and Grassi 1999; Zanchetti 1999).

The investigation of the renin–angiotensin system began with the discovery of renin in 1898 by Tiegerstedt and Bergman and was followed by the observation in 1940 that renin acted on a plasma protein substrate to catalyze the formation of a pressor peptide, angiotensin (Vane 1999). This plasma precursor is angiotensinogen and two forms of angiotensin, angiotensin I and II, were recognized in the mid 1950s. The conversion of inactive angiotensin I to the active angiotensin II occurs via ACE (Soubrier et al 1988). Since these initial discoveries, efforts to manipulate the renin–angiotensin system have resulted in the synthesis of the first orally effective ACE inhibitor, captopril. A series
of other ACE inhibitors have now been synthesized (Cushman et al 1977).

Thiazides are effective and inexpensive antihypertensive agents, but their use at full doses is associated with various side effects and low patient compliance (JNC-7 2003).

There are three distinct advantages associated with the combination of an ACE inhibitor and a diuretic (Mancia et al 1997; Zanchetti 1999). Firstly, this combination, utilizing a low-dose diuretic, reduces the probability of adverse metabolic effects often associated with the use of high-dose diuretic therapy (JNC-7 2003). ACE inhibitors are also known to effectively counteract the tendency of thiazide diuretics to lower serum potassium levels. In addition, HCTZ may increase oxidant activity via an activation of the renin–angiotensin system, and zofenopril has a direct antioxidant effect in humans (Napoli et al 2004).

Secondly, the use of a fixed combination reduces the number of tablets taken daily, thus improving patient compliance.

Thirdly, combination therapy may be, at least, as equally effective as monotherapy in the prevention of organ damage associated with hypertension. ACE inhibitor therapy in combination with a diuretic has been shown to be effective in reducing left ventricular hypertrophy (LVH) (Mancia et al 1997). In clinical trials in patients with hypertension and diabetes, an ACE inhibitor in combination with a diuretic plays a role in retarding the progression of renal failure in diabetic and other types of nephropathy (Lewis et al 1993; Giatras et al 1997; Zanchetti and Ruilope 2002).

**Clinical efficacy of Zofenopril–HCTZ**

Zofenopril, a new potent sulphydryl ACE inhibitor, is characterized by high lipophilicity, sustained cardiac ACE inhibition, antioxidant and tissue protective activities (Borghi and Ambrosioni 2000; Matarrese et al 2004) (Figure 1).

Hydrochlorothiazide is the 3,4-dihydro-derivative of chlorothiazide (Figure 1). It affects the renal tubular mechanisms of electrolyte resorption, directly increasing excretion of sodium. Indirectly, the diuretic action of HCTZ reduces plasma volume with consequent increases in plasma renin activity, aldosterone secretion and urinary potassium loss, and decreases in serum potassium (Reyes 2002).

The fixed-dose combination of zofenopril–HCTZ 30/12.5 mg/day is approved for the management of mild-to-moderate hypertension. In clinical studies this combination was more effective in maintaining BP reduction than either agent administered as monotherapy (Malacco and Omboni 2005; Parati et al 2005). This result was particularly evident in patients who were non-responsive to zofenopril monotherapy (Malacco and Omboni 2005).

Three pivotal studies have investigated the clinical efficacy of this combination (Malacco and Omboni 2005; Parati et al 2005). In all studies a stable baseline elevated BP was confirmed by repeated measurement of seated or standing SBP/DBP during a single-blind, placebo run-in period of 2 to 4 weeks duration. Inclusion criteria for these studies included a seated DBP of: 95 mmHg to 110 mmHg for the dose-response study (Parati et al 2005); 95 mmHg to 115 mmHg for the parallel-group comparative study (Study 1), and 90 mmHg to 110 mmHg for the non-responder group study (Study 2) (Malacco and Omboni 2005). Patients eligible for randomization to treatment were required to meet the criteria for seated DBP at inclusion and also for intra- and inter-visit variability (<10 mmHg). Randomized, double-blind treatment was given as a once daily regimen at the same time each day. BP was measured approximately 24 h after the previous dose by cuff sphygmomanometer.
and in the dose-response study by ambulatory BP monitoring (ABPM).

**Dose-response study**

The results of a 12-week multi-center dose-response study in 353 patients with essential hypertension demonstrated that combination therapy with zofenopril–HCTZ (30/12.5 mg/day or 60/12.5 mg/day) was more effective in maintaining continuous 24h BP control than either agent administered alone (Parati et al 2005).

Patients aged 18 to 75 years were randomized to double-blind treatment with zofenopril 15 mg, 30 mg or 60 mg, HCTZ 12.5 mg or 25 mg or their combination for 12 weeks. The primary efficacy endpoint, proportion of patients achieving office BP normalization (seated DBP <90 mmHg), was greater for the combination of zofenopril–HCTZ than either agent administered as monotherapy and reached significance at the 30/12.5 mg/day, 60/12.5 mg/day and 30/25 mg/day doses (p<0.05).

The combination of zofenopril–HCTZ 30/12.5 mg normalized BP in 57% of patients compared with a normalization rate of 33% for HCTZ 12.5 mg/day (p<0.05). A total of 76% of patients administered the 30/12.5 mg combination exhibited normalized BP or a DBP reduction ≥10 mmHg (responders) in contrast with 42% on HCTZ 12.5 mg/day (p<0.01). Further reductions were observed with zofenopril–HCTZ 60/12.5 mg/day but not when HCTZ was increased to 25 mg/day. Similar results were observed with regard to SBP also, even if this was not a primary goal of the study.

Both 24h and hourly changes in BP were greater with zofenopril–HCTZ 30/12.5 mg/day, 60/12.5 mg/day and 30/25 mg/day combination treatment than with either agent administered singly.

Furthermore, higher smoothness indices, evaluated by ABPM, indicated that combination therapy, in particular 30/12.5 mg/day and 30/25 mg/day, provided superior BP control over the dosing interval compared with monotherapy (Zanchetti et al 2006).

**Comparative studies**

Two international multi-center, randomized, double-blind, parallel-group studies have evaluated the combination of zofenopril–HCTZ 30/12.5 mg/day compared with monotherapy with zofenopril 30 mg/day (Malacco and Omboni 2005).

A 36-week comparison of zofenopril–HCTZ and zofenopril monotherapy demonstrated the superior efficacy of combination therapy in lowering BP in 463 patients aged 18 to 75 years with mild-to-moderate hypertension. Following a 4-week washout period, the 12-week efficacy endpoint of reduction in DBP and SBP, and the proportion of responders were significantly greater with combination therapy than zofenopril monotherapy (p<0.001).

A second study of 369 patients, 18 to 70 years of age, confirmed the efficacy of combination therapy in treating patients with mild-to-moderate hypertension who were not responsive to zofenopril monotherapy (Malacco and Omboni 2005). Following a 4-week placebo run-in phase, eligible patients were administered 4-weeks’ treatment with zofenopril 30 mg/day in a single-blind fashion. Non-responders (SBP ≥130 mmHg and DBP ≥85 mmHg and/or SBP reduction <20 mmHg and/or DBP reduction <10 mmHg) were then randomized to double-blind treatment with zofenopril–HCTZ 30/12.5 mg/day or zofenopril 30 mg/day for 8 weeks. Significantly greater and more consistent reductions in BP and higher response rates were reported with combination therapy than with zofenopril monotherapy. In those patients receiving zofenopril monotherapy BP reached a plateau at week 8 but continued to decrease in patients receiving combination therapy.

Finally, while these results are encouraging, further clinical data are needed to assess the long-term efficacy of the zofenopril–HCTZ combination on specific clinical outcomes.

**Zofenopril–HCTZ and end-organ protection**

In addition to hypertension and other CV risk factors (i.e., hyperlipidemia, diabetes) it has been recognized that activation of the renin–angiotensin–aldosterone system (RAAS) plays a role in the risk of CV disease-related morbidity and mortality (Toto et al 2004; Dzau 2005). Angiotensin II has been shown to have a direct effect on various tissues including endothelial, vascular and renal tissues (Toto et al 2004).

Pharmacological agents such as ACE inhibitors, that actively prevent the formation of angiotensin II, may therefore have a beneficial effect in terms of end-organ protection beyond their activity on BP. Data from clinical trials with an ACE inhibitor, such as the Heart Outcomes Prevention Evaluation (HOPE) study, confirm the efficacy of these agents in reducing the risk of CV death, myocardial infarction and stroke (Yusuf et al 2000).

No large randomized clinical trial has yet demonstrated the long-term efficacy of the zofenopril–HCTZ combination...
on CV morbidity and mortality. The main data on zofenopril efficacy come from the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) and SMILE-2, where patients received this agent in addition to standard therapy. In SMILE, 1556 patients with no history of congestive heart failure and presenting <24 after onset of symptoms were randomized to zofenopril 7.5–30 mg twice daily (bid.) and placebo. Incidence of death or severe congestive heart failure at 6 weeks was significantly reduced by zofenopril compared with placebo (7.1% vs 10.6%; p<0.05); the cumulative risk reduction was 34% (p=0.018). The risk reduction with zofenopril was 46% (p=0.018) for severe congestive heart failure and 25% (p=0.19) for death (Figure 2). After 1 year, the mortality rate was significantly lower in the zofenopril group than in the placebo group (10% vs 14.1%) with a risk reduction of 29% (p=0.011) (Figure 3) (Ambrosioni et al 1995). Similar results have been observed in a subgroup of patients affected by type 2 diabetes (Borghi et al 2003).

In SMILE-2, 1024 thrombolyzed patients with acute MI were randomized to receive oral zofenopril (30–60 mg/day) or lisinopril (5–10 mg/day), starting within 12 hours of completion of thrombolytic therapy and continuing for 42 days. The overall incidence of severe hypotension was 10.9% with zofenopril and 11.7% with lisinopril (p=0.38). The incidence of drug-related severe hypotension was slightly but significantly lower with zofenopril than with lisinopril (6.7 vs 9.8%, p=0.048). The 6-week mortality rate was 3.2% in the zofenopril group and 4.0% in the lisinopril group (p=0.38), and no significant differences were observed in the incidence of major cardiovascular complications or any safety variables between the 2 ACE inhibitors (Borghi and Ambrosioni 2003).

Moreover, the ischemic heart protective effect of zofenopril has been clearly demonstrated in different animal models (Frascarelli et al 2004; Evangelista and Manzini 2005; Leva et al 2006): the main proposed mechanisms of action are interference with bradykinin metabolism, preservation of protein sulfhydryl groups, and antioxidant activity.

It has also been suggested (but yet not demonstrated in humans) that the zofenopril–HCTZ combination may be used to treat congestive heart failure. Preclinical data show that, as with captopril, zofenopril significantly increases the myocardial expression of collagen type III and normalized the collagen type I/III ratio, thus preventing myocardial hypertrophy in spontaneous hypertensive rats. The hypertension related organ damage was more completely prevented by zofenopril–HCTZ than by the enalapril–HCTZ combination and it was related to an activation of endothelial nitric oxide (NO) synthase expression and to a normalization of the oxidative stress components due to angiotensin II inhibition (Gagnon et al 2004).

Dietary sodium restriction (similar to that achievable with HTCZ) increases the zofenopril-related attenuation of
left ventricular dysfunction induced by myocardial infarction (Westendorp et al 2004).

Preclinical data on combination therapy with zofenopril–HCTZ indicated that, as well as preventing the development of arterial hypertension, it provided more complete organ protection than the combination of enalapril–HCTZ (García-Estan et al 2006). This was demonstrated in a 8 week study in hypertensive rats by a reduction in mortality, and normalization of renal morphological and functional alterations including improvements in excretory parameters.

Other preclinical data suggest that HCTZ could also contribute to the cardiac and renal protective effect of zofenopril by increasing the concentration of its metabolite, zofenoprilat, in these target organs (Westendorp et al 2005).

Interestingly, part of the organ-damage protection offered by zofenopril may also be mediated by its antioxidant effect and this has been clearly shown in both laboratory models and in humans (Napoli et al 2004). For example, one clinical study demonstrated that zofenopril, as with other sulfhydryl compounds, was able to improve the oxidative balance in hypertensive patients. This effect was accompanied by a parallel increase in NO synthesis, counteracting the usual inactivation of NO by O₂ radical production and was not observed with enalapril (Scribner et al 2003). Furthermore, the negative effect of thiazides, of increasing free radical levels through induction of the renin–angiotensin system, could be counterbalanced by zofenopril’s antioxidant effect in the combination.

**Tolerability of Zofenopril–HCTZ**

In controlled clinical trials involving approximately 600 patients, adverse events observed with the combination of zofenopril–HCTZ were in line with those previously reported with zofenopril or HCTZ monotherapy (Borghi et al 2004). The most commonly reported adverse events were dizziness, headache, and cough, as would be expected with ACE inhibitor therapy. These adverse events were generally mild-to-moderate in severity and were not correlated with age or gender. Theoretically, the presence of the sulphhydryl group may be associated with an increased prevalence of dysgeusia, but available clinical data do not support the hypothesis that this side effect is more frequent with zofenopril than with other drugs of the same class (Zanchetti et al 2006).

In the dose-response study, a total of 9.9% of patients reported an adverse event; 64.3% of these events were of mild intensity (Parati et al 2005). In these patients 61.9% of adverse events were determined to be treatment-related but the majority of adverse events disappeared upon discontinuation of treatment. The occurrence of treatment-related adverse events was comparable among the treatment groups, and the most common adverse events were cough and polyuria. Treatment withdrawal occurred in only 1.7%
of patients. There were no increases in low-density lipoprotein cholesterol levels or triglycerides, blood glucose or uric acid levels with combination therapy.

Importantly, in two studies zofenopril–HCTZ 30/12.5 mg/day was at least as well tolerated as zofenopril 30 mg/day monotherapy with the combination having no detrimental effect on heart rate (Malacco and Omboni 2005).

Finally, even though the available safety data are encouraging, further clinical studies are needed to fully confirm the long-term safety of the zofenopril–HCTZ combination.

**Place of Zofenopril–HCTZ in the management of hypertension**

Hypertension is the most commonly occurring independent CV disease risk factor in the world (Kearney et al 2004). One of the primary challenges for physicians in the management of patients with hypertension is achieving target BP levels in clinical practice. Physicians are now more aware than ever before that optimal antihypertensive treatment should be effective, ensure timely reductions in BP levels, and be well tolerated to enhance patient compliance.

The use of combination therapy in the treatment of patients with hypertension is recommended by the ESH–ESC, JNC-7 and the World Health Organization–International Society of Hypertension (WHO–ISH) 2003 guidelines (ESH–ESC 2003; JNC-7 2003; WHO–ISH 2003). ESH–ESC and JNC-7 guidelines acknowledge that the majority of patients will require two or more antihypertensive agents to achieve target BP goals (ESH–ESC 2003; JNC-7 2003). Therefore, in patients with uncontrolled BP, physicians should consider initiating combination therapy either with two separate agents or as a fixed-dose combination. Combination therapy is also justified in certain patient populations with hypertension and co-morbidities (ie, diabetes, chronic kidney disease) for whom rapid reduction of BP is required (ESH–ESC 2003; JNC-7 2003).

The use of combination therapy as first-line treatment is increasing as BP goals for antihypertensive therapy are becoming more ambitious for all patients and, in particular, for patients at a higher risk of CV complications. While most guidelines (ESH–ESC 2003; JNC-7 2003) advocate the combination of two agents from different classes as an alternative to monotherapy, many physicians feel that this does not allow the freedom to vary the dose of the individual components according to patient response. It should be emphasized that for fixed-dose combinations the individual doses of each component have been selected on the basis of careful investigation to determine the dose that provides the greatest BP reductions with the lowest incidence of adverse events in the largest proportion of patients (Zanchetti 1999).

The use of fixed-dose combination therapy with an ACE inhibitor and a diuretic provides physicians with the means to achieve BP control without the need for prolonged and laborious dose-titrations necessary with initial monotherapy (Gavras and Rosenthal 2004).

The results of a dose-response study comparing zofenopril–HCTZ with each agent administered as monotherapy clearly demonstrate that a greater antihypertensive effect, in terms of the rate of patients with normalized DBP, is achieved with combination therapy. In addition, combined therapy provided sustained and consistent BP control over the entire 24 h dosing interval.

These results suggest that the combination of zofenopril–HCTZ may be indicated in patients who do not achieve target BP on zofenopril 30 mg/day or up to 25 mg/day of HCTZ. A well-designed study confirmed the greater BP lowering efficacy of zofenopril–HCTZ 30/12.5 mg/day versus zofenopril 30 mg/day monotherapy (Borghi et al 2004). The advantage of zofenopril–HCTZ combination therapy in normalizing BP was particularly evident in patients who were non-responsive to monotherapy (Malacco and Omboni 2005).

The overall tolerability profile of zofenopril–HCTZ is consistent with the profile of each individual agent. A direct comparison of zofenopril–HCTZ with each agent administered as monotherapy did not show any significant differences in the nature, severity or incidence of treatment-related adverse events (Malacco and Omboni 2005; Parati et al 2005). Headache, dizziness, cough and polyuria were the most frequently reported treatment-related adverse events. Neither patient gender nor age had any effect on the tolerability of the zofenopril–HCTZ combination. Notably, fewer patients discontinued treatment with combination therapy due to adverse events (Zanchetti et al 2006).

The fixed combination of zofenopril–HCTZ is expected to demonstrate potential additive cardiovascular protective properties as suggested by the efficacy of zofenopril monotherapy in reducing the incidence of death or severe congestive heart failure post myocardial infarction in the SMILE study (Ambrosioni et al 1995). Preclinical data
support its efficacy in providing cardiovascular and renal end-organ protection (Borghi et al 2004).

Nevertheless, as for all fixed-combination treatment there are also some potential disadvantages: firstly, the difficulty in modifying the dosage of any of the individual drug components according to BP response; secondly, the difficulty in distinguishing the causative agent in any cases of atypical side effects; and finally, administration of two drugs may also increase the risk of pharmacological interaction with other agents given concomitantly.

**Conclusion**

In conclusion, data from clinical trials with zofenopril–HCTZ indicate that this combination provides optimal BP control in a larger proportion of patients compared with monotherapy, whilst maintaining the tolerability profile observed with each individual component and thereby enhancing patient compliance. The efficacy and safety profile of zofenopril–HCTZ highlights that this combination is a useful addition to currently available therapy for patients with BP inadequately controlled by monotherapy, as well as for patients who require more rapid and intensive BP control. Further long-term large randomized clinical trials are needed to establish that the zofenopril–HCTZ combination has the same cardiovascular and renal protective effects demonstrated by other ACE inhibitors.

**Disclosure**

Five years ago Professor Borghi received funding to support research on Zofenopril efficacy and safety in clinical practice.

**References**

Ambrosioni E, Borghi C, Magnani B; for the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. 1995. The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med, 333:80-5.

Ambrosioni E, Leonetti G, Pessina AC, et al. 2000. Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy. J Hypertens, 18:1691-9.

Borghi C, Ambrosioni E. 2000. Zofenopril: A review of the evidence of its benefits in hypertension and acute myocardial infarction. Clin Drug Invest, 20:371-84.

Borghi C, Ambrosioni E; Survival of Myocardial Infarction Long-term Evaluation-2 Working Party. 2003. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J, 145:80-7.

Borghi C, Bacchelli S, Degli Esposti D, et al. 2004. A review of the angiotensin-converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases. Expert Opin Pharmacother, 5:1965-77.

Borghi C, Bacchelli S, Esposti DD, et al; SMILE Study. 2003. Effects of the early ACE inhibition in diabetic non-thrombolysed patients with anterior acute myocardial infarction. Diabetes Care, 26:1862-8.

Collins R, MacMahon S. 1994. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull, 50:272-98.

Cushman DW, Cheung HS, Sabo EF, et al. 1977. Design of potent competitive inhibition of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry, 16:5484-91.

Dzau V. 2005. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens, 23(Suppl 1):S9-S17.

[ESH–ESC] European Society of Hypertension – European Society of Cardiology Guidelines Committee. 2003. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens, 21:1011-53.

[EUROASCPIRE II] EUROASCPIRE II Euro Heart Survey Programme. 2001. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASCPIRE II Euro Heart Survey Programme. Eur Heart J, 22:554-72.

Evangelista S, Manzini S. 2005. Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J Int Med Res, 33:42-54.

Ezzati M, Lopez AD, Rodgers A, et al. 2002. Selected major risk factors and global and regional burden of disease. Lancet, 360:1347-60.

Franklin S, Larson MG, Khan SA, et al. 2001. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation, 103:1245-9.

Frascarelli S, Ghelardoni S, Ronca-Testoni S, et al. 2004. Cardioprotective effect of zofenopril in perfused rat heart subjected to ischemia and reperfusion. J Cardiovasc Pharmacol, 43:294-9.

Gagnon C, Legault F, Géralds P, et al. 2004. Diverse effects of ACE inhibitors and angiotensin II receptor antagonists on prevention of cardiac hypertrophy and collagen distribution in spontaneously hypertensive rats. Int J Cardiol, 97:373-81.

García-Estan J, Ortiz C, O’Valle F, et al. 2006. Effects of angiotensin converting enzyme inhibitors in combination with diuretics on blood pressure and renal injury in nitric oxide deficiency induced hypertension in rats. Clin Sci, 110:227-33.

Gavras I, Rosenthal T. 2004. Combination therapy as first-line treatment for hypertension. Curr Hypertens Rep, 6:267-72.

Giartas I, Lau J, Levey AS, et al. 1997. Effect of angiotensin-converting-enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials. Ann Intern Med, 127:337-45.

Hajjar I, Kotchen TA. 2003. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. J Am Med Assoc, 290:199-206.

Hansson L, Zanchetti A; for the HOT Study Group. 1997. The Hypertension Optimal Treatment (HOT) study: 24-month data on blood pressure and tolerability. Blood Pressure, 6:313-17.

Hansson L, Zanchetti A, Carruthers SG, et al. 1998. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet, 351:1755-62.

[HNC-7] Joint National Committee VII Committee, National Heart, Lung, and Blood Institute. 2003. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. NIH Publication No. 03-5233; May 2003.

Kearney PM, Whelton M, Reynolds K, et al. 2005. Global burden of hypertension: analysis of worldwide data. Lancet, 365:212-23.

Kearney PM, Whelton M, Reynolds K, et al. 2004. Worldwide prevalence of hypertension: a systematic review. J Hypertens, 22:11-19.
Khalil ME, Basher AW, Brown EJ JR, et al. 2001. A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients. *J Am Coll Cardiol*, 37:1757-64.

Leva C, Mariscalco G, Ferrarese S, et al. 2006. The role of zofenopril in myocardial protection during cardioplegia arrest: an isolated rat heart model. *J Card Surg*, 21:44-9.

Lewis EJ, Hunsicker LG, Bain RP, et al. 1993. The effect of angiotensin-converting-enzyme therapy on diabetic nephropathy. *N Engl J Med*, 329:1456-62.

Malacco E, Omboni S. 2005. Antihypertensive efficacy of zofenopril plus hydrochlorothiazide fixed combination is superior to that of single components. *Eur Heart J*, 26:401.

Mancia G, Grassi G. 1999. Rationale for the use of a fixed dose combination in the treatment of hypertension. *Eur Heart J Supplements*, 1(Suppl. L):L14-19.

Mancia G, Zanchetti A, Agabiti-Rosei E, et al. 1997. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. *Circulation*, 95:1464-70.

Matarrese M, Salimbeni A, Turolla EA, et al. 2004. 11C-Radiosynthesis and preliminary human evaluation of the disposition of the ACE inhibitor [11C]zofenoprilat. *Bioorg Med Chem*, 12:603-11.

Moser M. 2003. Rationale for combination therapy in the management of hypertension. *J Hypertens*, 23(Suppl 2):S309

Parati G, Omboni S, Malacco E, on behalf of the Study Group. 2005. Antihypertensive efficacy of zofenopril and hydrochlorothiazide and their different combinations assessed by 24h ambulatory blood pressure monitoring. *J Hypertens*, 23(Suppl 2):S309

Reyes AJ. 2002. Diuretics in the therapy of hypertension. *J Hum Hypertens*, 16(Suppl 1):S78-83.

Scribner AW, Loscalzo J, Napoli C 2003. The effect of angiotensin converting enzyme inhibition on endothelial function and oxidant stress. *Eur J Pharmacol*, 482:95-9.

Soubrier F, Alhenc-Gelas F, Hubert C, et al. 1988. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. *Proc Natl Acad Sci U S A*, 85:9386-90.

Toto RD, Rinner S, Ram CVS. 2004. ACE inhibitors and target organ protection. An expanded role for these antihypertensive agents? *Postgrad Med*, 116:11-16.

Vane JR. 1999. The history of inhibitors of angiotensin converting enzyme. *J Physiol Pharmacol*, 50:489-98.

Vasan RS, Larson MG, Leip EP, et al. 2001. Impact of high-normal blood pressure on the risk of cardiovascular disease. *N Engl J Med*, 345:1291-7.

Wang, TJ, Vasan RS. 2005. Epidemiology of uncontrolled hypertension in the United States. *Circulation*, 112:1651-62.

Westendorp B, Schoemaker RG, Buikema H, et al. 2004. Dietary sodium restriction specifically potentiates left ventricular ACE inhibition by zofenopril, and is associated with attenuated hypertrophic response in rats with myocardial infarction. *J Renin Angiotensin Aldosterone Syst*, 5:27-32.

Westendorp B, Schoemaker RG, van Gilst WH, et al. 2005. Hydrochlorothiazide increases plasma or tissue angiotensin-converting enzyme-inhibitor drug levels in rats with myocardial infarction: differential effects on lisinopril and zofenopril. *Eur J Pharmacol*, 527:141-9.

Wetzels, GEC, Nelemans P, Schouten JS, et al. 2004. Facts and fiction of poor compliance as a cause of inadequate blood pressure: a systematic review. *J Hypertens*, 22:1849-55.

[WHO–ISH] World Health Organization – International Society of Hypertension Writing Group. 2003. 2003 World Health Organization (WHO)–International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens*, 21:1983-92.

Yusuf S, Sleight P, Pogue J, et al. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. *N Engl J Med*, 342:145-53.

Zanchetti A. 1999. Contribution of fixed low-dose combinations to initial therapy in hypertension. *Eur Heart J Supplements*, 1(Suppl. L):L5-L9.

Zanchetti A, Parati G, Malacco E. 2006. Zofenopril plus hydrochlorothiazide. Combination therapy for the treatment of mild to moderate hypertension. *Drugs*, 66:1107-15.

Zanchetti A, Ruilope LM. 2002. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from well controlled randomized trials? *J Hypertens*, 20:2095-110.
